Introduction {#s1}
============

Primary immune thrombocytopenia (ITP) is the most common autoimmune cytopenia characterized by transient or persistent decreased platelet count ([@B6]; [@B4]). The occurrence of ITP results from the generation of anti-platelet autoantibodies against platelet membrane glycoproteins finally leading to the destruction of platelets in the reticuloendothelial system, especially in the spleen ([@B55]). ITP patients have an increased risk of bruising, cutaneous bleeding, and infrequently serious bleeding including intracranial hemorrhage ([@B28]). In addition, the quality of life of ITP patients is affected as a result of the physical and psychological symptoms, discomfort, fear, reduced social activity, and reduced ability to work ([@B31]). The standard therapy for newly diagnosed ITP patients is to stop bleeding and increase platelet counts using pharmaceutical medicines ([@B22]). However, these treatments are often accompanied by harmful side effects, which tend to be more evident with the time of treatment. In addition, the high treatment costs cast a heavy financial burden to ITP patients, especially those with severe forms of the disease ([@B19]).

In recent years, traditional Chinese medicine (TCM) has been regarded as a potential effective auxiliary strategy to treat the chronic diseases, including ITP ([@B11]). [@B14] reported that a modified Chinese herbal formula, Zi-Ying-Jiang-Huo-Tang (Phellodendri Combination) cured a 4-year-old ITP patient who did not respond to a 7-month first-line conventional treatment of steroids and intravenous immunoglobulin, and no recurrence of the disease or side effects of the treatment were found during the 12-month follow-up period. [@B50] reported that imbalance of Th1/Th2 and Th17/Treg cells play a crucial role in the pathogenesis of chronic ITP and that Yiqi Tongyang Decoction significantly regulated the dynamics of Th1/Th2 and Th17/Treg equilibria.

Yiqi Shexue formula (YQSX), an improved formula of Bazhen decoction (BZD), is a mixture of 9 Chinese medicine extracts including *Ginseng Radix et Rhizoma* (GRR, the dried root and rhizome of *Panax ginseng* C. A. Mey.), *Poria* \[P, the dried sclerotium of *Poria cocos* (Schw.) Wolf\], *Atractylodis Macrocephalae Rhizoma* (AMR, the dried rhizome of *Atractylodes macrocephala* Koidz.), *Glycyrrhizae Radix et Rhizoma* (RRG, the dried root and rhizome of *Glycyrrhiza uralensis* Fisch), *Angelicae Sinensis Radix* \[ASR, the dried root of *Angelica sinensis* (Oliv.) Diels\], *Chuanxiong Rhizoma* (CR, the dried rhizome of *Ligusticum chuanxiong* Hort.), *Paeoniae Radix Alba* (PRA, the dried root of *Paeonia lactiflora* Pall.), *Rehmanniae Radix Praeparata* (RRP, the dried root of *Rehmannia glutinosa* Libosch.), and *Asini Corii Colla* (ACC, the product of hide of *Equus asinus* L.). In TCM, BZD is frequently used to treat the deficiency of *qi* and *blood* which is characterized by many symptoms, including anemia, asthenia, dizziness, chronic abscess, fatigue, irregular menstruation, palpitations, fatigue of the muscles, and pale complexion ([@B41]). It has been reported that BZD could substantially promote the proliferation of bone marrow hematopoietic cells in anemic mice ([@B43]). YQSX is formulated based on BZD with one additional medicine (ACC). ACC is obtained from *Equus asinus Linnaeus* and has been widely used to promote health in China for life cultivation and clinical hematic antanemic therapy as a health food and TCM for more than 2,000 years. And early evidence has shown that ACC possesses a therapeutic effect in treating various hematologic diseases, such as anemia, aleucocytosis, and thrombopenia ([@B47]). In TCM, YQSX has been suggested to be able to invigorate *spleen*, replenish *qi*, nourish *blood*, and promote blood circulation and is traditionally used to treat ITP in clinical practice. However, the mechanisms of action and molecular targets of YQSX for treatment of ITP are not clear, which is the main factor limiting its wider use.

In TCM, complex herbal formulations that consist of multiple herbs are used and these complex chemical mixtures include numerous potential bioactive components that can interact with multiple therapeutic targets. This multi-component, multi-target, and multi-pathway approach may be ideal for the treatment of diseases with complex pathophysiology and therapeutic targets, but also present a tremendous challenge in understanding of the interactions between various components, their mechanisms of action and molecular targets. [@B29] proposed the concept of Network Pharmacology in an attempt to solve these problems. Network pharmacology is a novel approach that combines system network analysis and pharmacology. It could be used to elucidate the synergistic effects among compounds and potential mechanisms of multi-component and multiple target drugs at the molecular level through the networks of compound--compound, compound--target, and target--disease. Network pharmacology would facilitate the understanding of the interactions among the compounds, genes, proteins, and diseases and is suitable for the study of complex TCM formulations ([@B49]; [@B52]). [@B5] explored potential mechanism of Jiawei Foshou San on endometriosis using a network pharmacology approach. The underlying action mechanism of Wu-Tou decoction in rheumatoid arthritis was expounded by network pharmacology prediction and experimental verification ([@B10]). The potential mechanism between Danggui-shaoyao-san and neurodegenerative disorders was deciphered through a network pharmacology approach ([@B33]). The research group of Shao Li elucidated anti-rheumatic mechanisms of Qing-Luo-Yin and investigated its possible interactions with methotrexate using an integrating strategy coupled with network pharmacology and metabolomics techniques ([@B60]).

In the present study, a network pharmacology approach was used to explore the mechanisms of action and molecular targets of YQSX for treatment of ITP. The active compounds of YQSX and their targets were firstly identified using drugbank database. Then ITP-related targets were obtained by analyzing the differential expressed genes between ITP patients and healthy individuals. The mechanisms of action underlying YQSX for the treatment of ITP were analyzed by gene ontology (GO) and pathway analysis.

Materials and Methods {#s2}
=====================

Active Ingredients Screening {#s2_1}
----------------------------

We identified the chemical composition of YQSX from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform ([@B40]) (TCMSP, <http://lsp.nwu.edu.cn/tcmsp.php>) and select candidate compounds which has oral bioavailability (OB) ≥ 30% and drug-likeness (DL) ≥ 0.18 ([@B24]). One hundred and sixty eligible compounds were obtained, 22 in GRR, 15 in P, 7 in AMR, 92 in RRG, 2 in ASR, 7 in CR, 13 in PRA, and 2 in RRP. However, 8 compounds including ferulic acid, ligustilide, senkyunolide C, and leonuride which were not found in the database have been selected as they have the pharmacological activity on ITP treatment. Additionally, 19 amino acids including aspartic acid, threonine, and serine in ACC have been reported to process relevant pharmacological properties and were also included ([@B47]). Eventually, 177 candidate compounds were obtained in total after the duplications were removed.

Identification of Potential Targets {#s2_2}
-----------------------------------

The 177 candidate compounds were imported into the DrugBank database ([@B23]) (<https://www.drugbank.ca/>) to identify the corresponding targets of YQSX. One hundred and forty-eight compounds were finally selected after removing 29 compounds which did not link to any targets. And the targets of 148 compounds were collected. Two thousand one hundred and seventy-seven targets were identified, 204 in GRR, 28 in P, 20 in AMR, 1272 in RRG, 106 in ASR, 36 in CR, 99 in PRA, 58 in RRP, and 354 in ACC. A total of 251 targets were collected after removing duplication.

ITP-Related Targets {#s2_3}
-------------------

The differential expressed genes of ITP patients were obtained from GEO database (<https://www.ncbi.nlm.nih.gov/geo/>, Series: GSE574, Samples: GSM8814, GSM8815, GSM8816, GSM8817). Genes with a *P* value \< 0.005 and \|log 2(fold change)\| \> 1 were considered to be of significantly differential expression and ITP-related targets.

Network Construction {#s2_4}
--------------------

The compound-target network of YQSX was constructed and visualized using Cytoscape 3.5.1 software. PPI data were obtained from Database of Interacting Proteins (DIP™), Biological General Repository for Interaction Datasets (BioGRID), Human Protein Reference Database (HPRD), IntAct Molecular Interaction Database (IntAct), Molecular INTeraction database (MINT), and biomolecular interaction network database (BIND) using the plugin Bisogenet ([@B34]) of Cytoscape 3.5.1 software. The PPI networks of YQSX putative targets and ITP-related targets were visualized with Cytoscape software.

Network Merge {#s2_5}
-------------

The PPI networks of YQSX putative targets and ITP-related targets were merged with Cytoscape software. And the nodes with topological importance in the interaction network were screened by calculating Degree Centrality (DC), Betweenness Centrality (BC), Closeness Centrality (CC), Eigenvector Centrality (EC), Local average connectivity-based method (LAC), and Network Centrality (NC) with the Cytoscape plugin CytoNCA. These parameters represent the topological importance and they have been reported about their definitions and computational formulas and used in network pharmacology and systems pharmacology ([@B42]).

Bioinformatic Analysis {#s2_6}
----------------------

GO analysis with the biological process, cellular component, and molecular function was carried out using the Database for Annotation, Visualization and Integrated Discovery (DAVID, <https://david.ncifcrf.gov>, v6.8) ([@B13]). Functional categories were enriched within genes (FDR \< 0.05) and the top 20 GO functional categories were selected. DAVID that assigned Kyoto Encyclopedia of Genes and Genomes (KEGG) database was used for pathway analysis. Pathways that had significant changes of FDR \< 0.05 were identified for further analysis. The genes that significantly regulated pathways were selected for gene-pathway network analysis. The gene-pathway network was constructed to screen the key target genes that YQSX treated ITP.

Results {#s3}
=======

Compound-Target Network Analysis {#s3_1}
--------------------------------

One hundred and forty-eight compounds of YQSX ([**Table 1**](#T1){ref-type="table"}) were finally selected as the candidate compounds. And 230 ITP-related targets were identified from GEO database. As shown in [**Figure 1**](#f1){ref-type="fig"}, a volcano plot was created to show the distribution of differentially expressed genes, which were represented by the red dots in the plot.

###### 

The final selected compounds in YQSX for analysis.

  ID          Name                                                                                                                                                            OB      DL     Source              ID          Name                                                                                                    OB      DL     Source
  ----------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- ------- ------ ------------------- ----------- ------------------------------------------------------------------------------------------------------- ------- ------ ---------
  MOL000449   Stigmasterol                                                                                                                                                    43.83   0.76   GRR, ASR, RRP       MOL004908   1,3-dihydroxy-8,9-dimethoxy-6-benzofurano\[3,2-c\]chromenone                                            62.9    0.53   RRG
  MOL000358   ß-sitosterol                                                                                                                                                    36.91   0.75   GRR, ASR, PRA       MOL004910   (2R)-7-hydroxy-2-(4-hydroxyphenyl)chroman-4-one                                                         71.12   0.18   RRG
  MOL003648   Inermin                                                                                                                                                         65.83   0.54   GRR                 MOL004911   Glabrene                                                                                                46.27   0.44   RRG
  MOL005317   Deoxyharringtonine                                                                                                                                              39.27   0.81   GRR                 MOL004912   Glabrone                                                                                                52.51   0.5    RRG
  MOL005320   Arachidonate                                                                                                                                                    45.57   0.2    GRR                 MOL004913   Hedysarimcoumestan B                                                                                    48.14   0.43   RRG
  MOL005321   Frutinone A                                                                                                                                                     65.9    0.34   GRR                 MOL004914   Glabridin                                                                                               53.25   0.47   RRG
  MOL005356   Girinimbine                                                                                                                                                     61.22   0.31   GRR                 MOL004915   Eurycarpin A                                                                                            43.28   0.37   RRG
  MOL005376   Panaxadiol                                                                                                                                                      33.09   0.79   GRR                 MOL004924   (-)-Medicocarpin                                                                                        40.99   0.95   RRG
  MOL005384   Suchilactone                                                                                                                                                    57.52   0.56   GRR                 MOL004935   Sigmoidin B                                                                                             34.88   0.41   RRG
  MOL000787   Fumarine                                                                                                                                                        59.26   0.83   GRR                 MOL004941   Glabranin                                                                                               52.9    0.31   RRG
  MOL002879   Diop                                                                                                                                                            43.59   0.39   GRR                 MOL004945   Isobavachin                                                                                             36.57   0.32   RRG
  MOL000422   Kaempferol                                                                                                                                                      41.88   0.24   GRR, PRA, RRG       MOL004948   Isoglycyrol                                                                                             44.7    0.84   RRG
  MOL005308   Aposiopolamine                                                                                                                                                  66.65   0.22   GRR                 MOL004949   Isolicoflavonol                                                                                         45.17   0.42   RRG
  MOL005344   Ginsenoside Rh2                                                                                                                                                 36.32   0.56   GRR                 MOL004957   Isoformononetin                                                                                         38.37   0.21   RRG
  MOL005348   Ginsenoside Rh4                                                                                                                                                 31.11   0.78   GRR                 MOL001484   Inermine                                                                                                75.18   0.54   RRG
  MOL005318   Dianthramine                                                                                                                                                    40.45   0.2    GRR                 MOL004959   1-Methoxyphaseollidin                                                                                   69.98   0.64   RRG
  MOL005399   Daucosterol                                                                                                                                                     36.91   0.75   GRR                 MOL004993   8-prenylated eriodictyol                                                                                53.79   0.4    RRG
  MOL000676   Dibutyl Phthalate                                                                                                                                               64.54   0.13   GRR, PRA            MOL004961   Quercetin der.                                                                                          46.45   0.33   RRG
  MOL000273   (3ß,16α)-3,16-Dihydroxylanosta-7,9(11),24-trien-21-oic acid                                                                                                     30.93   0.81   P                   MOL004966   7,2′,4′-trihydroxy-5-methoxy-3-arylcoumarin                                                             83.71   0.27   RRG
  MOL000275   Trametenolic acid                                                                                                                                               38.71   0.8    P                   MOL000497   Licochalcone A                                                                                          40.79   0.29   RRG
  MOL000279   Cerevisterol                                                                                                                                                    37.96   0.77   P                   MOL004974   3′-Methoxyglabridin                                                                                     46.16   0.57   RRG
  MOL000282   Stellasterol                                                                                                                                                    43.51   0.72   P                   MOL004978   4′-Methoxyglabridin                                                                                     36.21   0.52   RRG
  MOL000283   Ergosterol peroxide                                                                                                                                             40.36   0.81   P                   MOL004980   Inflacoumarin A                                                                                         39.71   0.33   RRG
  MOL000296   Hederagenin                                                                                                                                                     36.91   0.75   P                   MOL004985   Icos-5-enoic acid                                                                                       30.7    0.2    RRG
  MOL000022   14-acetyl-12-senecioyl-2E,8Z,10E-atractylentriol                                                                                                                63.37   0.3    AMR                 MOL004988   Kanzonol F                                                                                              32.47   0.89   RRG
  MOL000033   (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-\[(2R,5S)-5-propan-2-yloctan-2-yl\]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta\[a\]phenanthren-3-ol   36.23   0.78   AMR                 MOL004989   (2S)-6-(2,4-dihydroxyphenyl)-2-(2-hydroxypropan-2-yl)-4-methoxy-2,3-dihydrofuro\[3,2-g\]chromen-7-one   60.25   0.63   RRG
  MOL000049   3ß-acetoxyatractylone                                                                                                                                           54.07   0.22   AMR                 MOL004990   3′-Hydroxy-4′-O-Methylglabridin                                                                         43.71   0.57   RRG
  MOL000072   8ß-ethoxy atractylenolide III                                                                                                                                   35.95   0.21   AMR                 MOL004991   7-Acetoxy-2-methylisoflavone                                                                            38.92   0.26   RRG
  MOL001792   Liquiritigenin                                                                                                                                                  32.76   0.18   RRG                 MOL004996   Gadelaidic acid                                                                                         30.7    0.2    RRG
  MOL000211   Mairin                                                                                                                                                          55.38   0.78   RRG, PRA            MOL000500   Vestitol                                                                                                74.66   0.21   RRG
  MOL002311   Glycyrol                                                                                                                                                        90.78   0.67   RRG                 MOL005000   Gancaonin G                                                                                             60.44   0.39   RRG
  MOL000239   Jaranol                                                                                                                                                         50.83   0.29   RRG                 MOL005001   Gancaonin H                                                                                             50.1    0.78   RRG
  MOL002565   Medicarpin                                                                                                                                                      49.22   0.34   RRG                 MOL005003   Licoagrocarpin                                                                                          58.81   0.58   RRG
  MOL000354   Isorhamnetin                                                                                                                                                    49.6    0.31   RRG                 MOL005007   Glyasperins M                                                                                           72.67   0.59   RRG
  MOL000359   Sitosterol                                                                                                                                                      36.91   0.75   RRG, CR, RRP, PRA   MOL005008   Glycyrrhiza flavonol A                                                                                  41.28   0.6    RRG
  MOL003656   Lupiwighteone                                                                                                                                                   51.64   0.37   RRG                 MOL005012   Licoagroisoflavone                                                                                      57.28   0.49   RRG
  MOL003896   7-Methoxy-2-methyl isoflavone                                                                                                                                   42.56   0.2    RRG                 MOL005016   Odoratin                                                                                                49.95   0.3    RRG
  MOL000392   Formononetin                                                                                                                                                    69.67   0.21   RRG                 MOL005017   Phaseol                                                                                                 78.77   0.58   RRG
  MOL000417   Calycosin                                                                                                                                                       47.75   0.24   RRG                 MOL005018   Xambioona                                                                                               54.85   0.87   RRG
  MOL004328   Naringenin                                                                                                                                                      59.29   0.21   RRG                 MOL005020   Dehydroglyasperins C                                                                                    53.82   0.37   RRG
  MOL004805   Shinflavanone                                                                                                                                                   31.79   0.72   RRG                 MOL000098   Quercetin                                                                                               46.43   0.28   RRG
  MOL004806   Euchrenone                                                                                                                                                      30.29   0.57   RRG                 MOL000360   Ferulic acid                                                                                            39.56   0.06   ASR, CR
  MOL004808   Glyasperin B                                                                                                                                                    65.22   0.44   RRG                 MOL011782   Ligustilide                                                                                             23.5    0.07   ASR, CR
  MOL004810   Glyasperin F                                                                                                                                                    75.84   0.54   RRG                 MOL002143   Senkyunolide-C                                                                                          46.8    0.08   ASR, CR
  MOL004811   Glyasperin C                                                                                                                                                    45.56   0.4    RRG                 MOL002111   3-Butylidenephthalide                                                                                   42.44   0.07   ASR, CR
  MOL004814   Isotrifoliol                                                                                                                                                    31.94   0.42   RRG                 MOL001494   Mandenol                                                                                                42      0.19   CR
  MOL004815   Kanzonol B                                                                                                                                                      39.62   0.35   RRG                 MOL002135   Myricanone                                                                                              40.6    0.51   CR
  MOL004820   Kanzonol W                                                                                                                                                      50.48   0.52   RRG                 MOL002140   Perlolyrine                                                                                             65.95   0.27   CR
  MOL004824   6-prenylated eriodictyol                                                                                                                                        39.22   0.41   RRG                 MOL002157   Wallichilide                                                                                            42.31   0.71   CR
  MOL004827   Semilicoisoflavone B                                                                                                                                            48.78   0.55   RRG                 MOL000433   Folic Acid                                                                                              68.96   0.71   CR
  MOL004828   Glepidotin A                                                                                                                                                    44.72   0.35   RRG                 MOL001918   Paeoniflorigenone                                                                                       87.59   0.37   PRA
  MOL004829   Glepidotin B                                                                                                                                                    64.46   0.34   RRG                 MOL001919   Palbinone                                                                                               43.56   0.53   PRA
  MOL004833   Phaseolinisoflavan                                                                                                                                              32.01   0.45   RRG                 MOL001924   paeoniflorin                                                                                            53.87   0.79   PRA
  MOL004835   Glypallichalcone                                                                                                                                                61.6    0.19   RRG                 MOL000492   Cianidanol                                                                                              54.83   0.24   PRA
  MOL004838   Glabrocoumarone A                                                                                                                                               58.44   0.38   RRG                 MOL000748   5-(Hydroxymethyl)-2-furaldehyde                                                                         45.07   0.02   RRP
  MOL004841   Licochalcone B                                                                                                                                                  76.76   0.19   RRG                 MOL001436   Leonuride                                                                                               2.6     0.33   RRP
  MOL004848   Licochalcone G                                                                                                                                                  49.25   0.32   RRG                 MOL002819   Catalpol                                                                                                5.07    0.44   RRP
  MOL004849   Licoarylcoumarin                                                                                                                                                59.62   0.43   RRG                 MOL000067   Valine                                                                                                  53.33   0.01   ACC
  MOL004855   Licoricone                                                                                                                                                      63.58   0.47   RRG                 MOL007579   Hydroxyproline                                                                                          83.55   0.02   ACC
  MOL004856   Gancaonin A                                                                                                                                                     51.08   0.4    RRG                 MOL000061   Proline                                                                                                 77.57   0.01   ACC
  MOL004857   Gancaonin B                                                                                                                                                     48.79   0.45   RRG                 MOL000050   Glycine                                                                                                 48.74   0      ACC
  MOL004863   Gancaonin L                                                                                                                                                     66.37   0.41   RRG                 MOL000071   Histidine                                                                                               53.18   0.03   ACC
  MOL004864   Gancaonin M                                                                                                                                                     30.49   0.41   RRG                 MOL000054   Arginine                                                                                                47.64   0.03   ACC
  MOL004866   Gancaonin O                                                                                                                                                     44.15   0.41   RRG                 MOL003971   Threonine                                                                                               73.52   0.01   ACC
  MOL004879   Glycyrin                                                                                                                                                        52.61   0.47   RRG                 MOL003969   Serine                                                                                                  98.5    0.01   ACC
  MOL004882   Licocoumarone                                                                                                                                                   33.21   0.36   RRG                 MOL000052   Glutamic Acid                                                                                           6.66    0.02   ACC
  MOL004883   Licoisoflavone                                                                                                                                                  41.61   0.42   RRG                 MOL000042   Alanine                                                                                                 87.69   0.01   ACC
  MOL004884   Licoisoflavone B                                                                                                                                                38.93   0.55   RRG                 MOL005449   Methionine                                                                                              70.87   0.01   ACC
  MOL004885   Licoisoflavanone                                                                                                                                                52.47   0.54   RRG                 MOL005448   Leucine                                                                                                 72.92   0.01   ACC
  MOL004891   Shinpterocarpin                                                                                                                                                 80.3    0.73   RRG                 MOL000068   Isoleucine                                                                                              59.05   0.02   ACC
  MOL004898   5-Prenylbutein                                                                                                                                                  46.27   0.31   RRG                 MOL000056   Tyrosine                                                                                                57.55   0.05   ACC
  MOL004903   Liquiritin                                                                                                                                                      65.69   0.74   RRG                 MOL000041   Phenylalanine                                                                                           41.62   0.04   ACC
  MOL004904   Licopyranocoumarin                                                                                                                                              80.36   0.65   RRG                 MOL000065   Aspartic Acid                                                                                           79.74   0.02   ACC
  MOL004907   Glyzaglabrin                                                                                                                                                    61.07   0.35   RRG                 MOL001780   Tryptophane                                                                                             75.93   0.08   ACC

OB, oral bioavailability; DL, drug-likeness; GRR, Ginseng Radix et Rhizoma; P, Poria; AMR, Atractylodis Macrocephalae Rhizoma; RRG, Glycyrrhizae Radix et Rhizoma; ASR, Angelicae Sinensis Radix; CR, Chuanxiong Rhizoma; PRA, Paeoniae Radix Alba; RRP, Rehmanniae Radix Praeparata; ACC, Asini Corii Colla.

![Volcano plot of differentially expressed genes. The abscissa represents the fold changes in gene expression and the ordinate represents the statistical significance of the variations in gene expression. The red dots represent significantly differentially expressed genes.](fphar-10-01136-g001){#f1}

The Compound-target network of YQSX was constructed using the screened compounds and their targets as shown in [**Figure 2**](#f2){ref-type="fig"}. The network contained 399 nods (148 compounds in YQSX and 251 compound targets) and 2,177 edges which indicated the compound-target interactions. One hundred and forty-eight candidate compounds had a median of 12 degrees, which suggested that most compounds of YQSX affected multiple targets. Kaempferol, glycine, and stigmasterol acted on 118, 99 and 87 targets, respectively. And the OB of kaempferol, glycine, and stigmasterol is 41.88, 48.74, and 43.83%, respectively. Therefore, they might be the crucial active compounds of YQSX by reason of their considerable positioning in the network.

![Compound- target network of YQSX. The blue triangles represent targets; the yellow, pink, cyan, kelly green, green, orange, red, gray, and violet ovals represent the compounds from GRR, P, AMR, RRG, ASR, CR, PRA, RRP, and ACC, respectively.](fphar-10-01136-g002){#f2}

PPI Networks Analysis {#s3_2}
---------------------

PPI operates large-scale biological processes, such as cell-to-cell interactions, metabolic control, and developmental control, and is increasingly regarded as the primary objectives of system biology ([@B38]). Therefore, PPI networks of YQSX putative targets and ITP-related targets were visualized using PPI data. The PPI network of YQSX putative targets contained 5,959 nodes and 148,332 edges, which represented 5,959 interacting protein and 148,332 interactions. The PPI network of ITP-related targets contained 5,163 nodes and 127,564 edges.

Identification of Candidate Targets for YQSX Against ITP {#s3_3}
--------------------------------------------------------

In order to reveal the mechanisms of action underling YQSX's effects on ITP, the PPI network of YQSX putative targets and the PPI network of ITP-related targets were merged to identify the candidate targets for YQSX against ITP. This network consisting of 3,232 nodes and 95,775 edges was presented in [**Figure 3A**](#f3){ref-type="fig"}. The median degree of all nodes was 37 and the nodes with more than 74 degrees were identified as significant targets according to the previous research ([@B54]). A network of significant targets for YQSX against ITP was constructed and it contained 780 nodes and 35,907 edges ([**Figure 3B**](#f3){ref-type="fig"}). The median values of DC, BC, CC, EC, LAC, and NC were 117, 6,403.125, 0.318309, 0.024411, 19.61376, and 27.984, respectively. The candidate targets were further screened and 183 targets with DC \> 117, BC \> 6,403.125, CC \> 0.318309, EC \> 0.024411, LAC \> 19.61376, and NC \> 27.984 were identified ([**Figure 3C**](#f3){ref-type="fig"}). One hundred and eighty-three target genes were eventually identified for YQSX against ITP.

![Identification of candidate targets of YQSX against ITP. **(A)** The interactive PPI network of YQSX putative targets and ITP-related targets. **(B)** PPI network of significant proteins extracted from A. **(C)** PPI network of candidate YQSX targets for ITP treatment extracted from B. DC, degree centrality; BC, betweenness centrality; CC, closeness centrality; EC, eigenvector centrality; LAC, local average connectivity-based method; NC, network centrality.](fphar-10-01136-g003){#f3}

GO and Pathway Enrichment Analysis {#s3_4}
----------------------------------

DAVID was used to perform GO and KEGG pathway analysis of the 183 candidate targets identified. GO of candidate targets was analyzed based on biological process, cellular component, and molecular function. One hundred seventy-two GO terms were significantly enriched (FDR \< 0.05), 98 in biological process, 29 in cellular component, and 45 in molecular function. The data of GO analysis were shown in [**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}. Top 20 terms were shown in [**Figure 4**](#f4){ref-type="fig"}. The highly enriched GO terms in biological process, cellular component, and molecular function included regulation of gene silencing, regulation of gene expression, nucleoplasm, nucleus, protein binding, and ubiquitin protein ligase binding.

![Gene ontology terms of candidate targets of YQSX against ITP. The top 20 GO functional categories with FDR \< 0.05 were selected.](fphar-10-01136-g004){#f4}

The pathways that were significantly influenced by YQSX in the process of treating ITP were identified by KEGG pathway analysis. Twenty-four significantly enriched pathways (FDR \< 0.05) including Epstein-Barr virus infection, cell cycle, estrogen signaling pathway, pathway in cancer, and MAPK signaling pathway were identified. The data of KEGG pathway analysis were shown in [**Supplementary Table 2**](#SM2){ref-type="supplementary-material"}. As shown in [**Figure 5**](#f5){ref-type="fig"}, size of the spot represented number of genes and color represented FDR value.

![KEGG pathway enrichment of candidate targets of YQSX against ITP. Pathways that had significant changes of FDR \<0.05 were identified. Size of the spot represents number of genes and color represents FDR value.](fphar-10-01136-g005){#f5}

Gene-Pathway Network Analysis {#s3_5}
-----------------------------

The gene-pathway network was constructed based on the significantly enriched pathways and genes that regulated these pathways, which was presented in [**Figure 6**](#f6){ref-type="fig"}. The topological analysis of 24 pathways and 115 genes was carried out with BC. The squares represented target genes and the V-shapes represented pathways in the network. The network diagram suggested that MDM2 had the most maximum BC and was the core target gene. Other several genes also had larger BC, such as TP53, MAPK1, CDKN1A, MYC, and DDX5. They might be the key target gens for YQSX against ITP.

![Gene-Pathway Network of YQSX against ITP. The topological analysis of 24 pathways and 115 genes was carried out with betweenness centrality. The yellow squares represent target genes and the red V-shapes represent pathways. Big size represents the larger betweenness centrality.](fphar-10-01136-g006){#f6}

Discussion {#s4}
==========

The unique medical theory of TCM has been formed and developed over thousands of years in China for the treatment and preventions of diseases. Multiple compatible herbs are usually used as complex herbal formulations to improve therapeutic effect through synergism ([@B25]). In TCM, ITP is thought to be a disease caused by the failure of *spleen* to manage blood. Guipi decoction and BZD were the most common prescribed formulas in the treatment of ITP in TCM. YQSX, the improved formula of BZD, is an empirical formula to treat ITP in TCM clinical practice, and has demonstrated significant clinical effects. Compared with BZD, ACC is added to YQSX. ACC has been shown to enrich the *blood* and to improve hemorheology, hemostasis, and immunological regulation, and its addition has further strengthened the BZD's effects for the treatment of ITP. TCM adopts a holistic approach focusing on overall functional recovery and elimination of the cause of the disease. The concept of network pharmacology is comparable to TCM theory and is therefore appropriate to be used for the research on unknown components and mechanism of action of complex TCM herbal formulations supported by a variety of databases and software available.

In the present study, a compound-target network of YQSX was constructed using the 148 compounds and 251 compound targets. The results suggested that most compounds of YQSX affected multiple targets, for example, kaempferol, glycine, and stigmasterol acted on 118, 99, and 87 targets, respectively. Therefore, they were very likely to be the crucial pleiotropically active compounds for YQSX. Although the number of putative targets in each single herb was different, the overlapping targets in different herbs were numerous. In another word, multiple compounds of YQSX may have the same target providing synergistic effects. Kaempferol is a representative flavonoid and has been shown to exert multiple pharmacological activities, such as antioxidant, anti-inflammatory, anti-cancer, anti-diabetic, anti-osteoarthritic, and immunomodulatory properties ([@B44]; [@B48]). [@B27] reported that kaempferol might be a potent immunosuppressant to decrease the harmful immune responses, including chronic inflammation and autoimmunity. Glycine is an important amino acid contributing to metabolism, growth, development, immunity, cytoprotection, and survival owning to its anti-inflammatory and immunomodulatory properties ([@B32]; [@B12]). Stigmasterol also showed anti-cancer, anti-inflammatory and anti-allergic properties as well as the modulatory effects on immune responses ([@B1]). TCM is a highly complex system and contains a large number of constituents. Researchers try to verify even more effective chemical components from TCM through various approaches including network pharmacology. But there has not been a way to recognize the total effective constituents of TCM up till the present moment. It is well known that the effects of TCM on treating diseases are the result of the combination effects of many constituents. In the present study, kaempferol, glycine, and stigmasterol regulated the most targets associated with ITP and all of them have immunomodulatory properties. Although kaempferol, glycine, and stigmasterol are ubiquitous and widely known compounds, there is some evidence for their immunomodulatory effects. In addition, they have high oral bioavailability and kaempferol and stigmasterol came from 3 herbs of YQSX. Therefore, they might be identified as the representative compounds for YQSX.

The PPI networks of YQSX putative targets and ITP-related targets were structured and merged to obtain the candidate targets for YQSX against ITP. In order to get the more accurate targets, 6 parameters including DC, BC, and CC were set to screen nodes and structure a new network. One hundred and eighty-three targets were finally identified and used to carry out the bioinformatic analysis to elucidate the mechanisms underlying the anti-ITP effects of YQSX.

The targets of YQSX against ITP were enriched in biological processes, cellular components, and molecular function by GO enrichment analysis. Results suggested that YQSX regulated some biological processes, such as gene silencing, gene expression, apoptotic process, and signal transduction by p53 class mediator. ITP is an autoimmune disease characterized by an abnormality in T cell immunity and T cell mechanism has been proved to be an important pathophysiologic mechanism in ITP ([@B17]; [@B18]). It has been shown that allogenic T cell responses could be inhibited through the production of immunoregulatory dendritic cells resulted by silencing RelB ([@B53]). The expression of CD72 and IL-2 was decreased whilst the IFN-γ/IL-4 expression was increased in ITP patients ([@B58]). Apoptotic process plays an important role in maintenance of normal immune system development, and a failure of apoptotic function has been shown to be associated with the pathogenesis of ITP ([@B37]). It has been found that mesenchymal stem cells from ITP patients showed increased apoptosis and a defect in immunoregulation and the apoptotic rate was decreased by inhibiting the expression of p53 ([@B56]). Therefore, YQSX may help to regulate immunological function through intervening these biological/pathological processes. It has been suggested that the pathogenesis of ITP was associated with gene expression, regulation of apoptosis, regulation of cell proliferation, nucleoplasm, transcription factor binding, histone deacetylase binding, protein kinase binding, and core promoter binding ([@B7]; [@B59]), all of which were significantly enriched in the present study. Therefore, YQSX may exert regulatory function in the pathogenesis of ITP and may also affect some cellular components and molecular function including nucleoplasm, nucleus, cytosol, protein binding, enzyme binding, and DNA binding in the treatment of ITP. Studies have found that the ultrastructural abnormalities in cytoplasmic vacuolization, mitochondrial swelling, abnormal chromatin condensation, and increased staining for activated caspase-3 in megakaryocytes also occur in ITP patients ([@B21]).

TCM is multi-component, multi-target, and multi-pathway. YQSX, as a TCM formula, also has the same characteristic. Therefore, it can be sure that YQSX treats ITP through multi-pathway. In the present study, a total of 24 KEGG pathways including MAPK signaling pathway and PI3K-AKT signaling pathway were significantly enriched. MAPKs can regulate gene expression, immune response, cell proliferation, apoptosis, and response to oxidative stress, which is one of the mechanisms of immune regulation ([@B26]). Research suggested that PI3K-AKT signaling pathways played a role in reducing excessive innate immune responses and crosstalk between MAPK, which was one of the mechanisms to balance the innate immune responses ([@B39]). Eltrombopag is a thrombopoietin receptor agonist and has been used to treat the thrombocytopenia of ITP. The signaling mechanisms of eltrombopag are involved in AKT and MAPK pathways, which is similar to that of thrombopoietin ([@B20]). Therefore, YQSX may regulate immunological function through the related pathways in the process of ITP treatment. In this study, several pathways related to viral also were significantly enriched. The viral infection relates to the genesis of ITP. The body's autoimmune response is activated when infected with virus, such as Human Immunodeficiency Virus, Hepatitis C Virus, Epstein-Barr virus, Cytomegalovirus, Herpes simplex virus, and Varicella zoster virus, and the autoimmune response will perpetuate itself despite viral clearance ([@B2]). The autoimmune response triggered by viral infection might be regulated by YQSX through specific pathways, such as Epstein-Barr virus infection, viral carcinogenesis, Hepatitis B, HTLV-I infection, and Herpes simplex infection. In a human study, plasma samples from 74 ITP patients and 58 healthy controls were collected and bioinformatic analysis was carried out. The results indicated that the occurrence of ITP was associated with proteoglycans in cancer, prostate cancer, glioma, thyroid hormone signaling pathway, and estrogen signaling pathway ([@B59]). In the present study, the aforementioned pathways were also significantly enriched, which suggested that the regulation of pathways associated with the occurrence of ITP might be one of the mechanisms of YQSX for treatment of ITP. In addition, YQSX may function by regulating other pathways, including cell cycle, and neurotrophin and ErbB signaling pathways. Inhibition of cell cycle caused by selective inhibition of lymphocyte proliferation was found to be beneficial for treating refractory ITP ([@B9]).

Gene-pathway network was constructed to investigate the core and key target genes for YQSX against ITP. Results suggested that MDM2 had the maximum BC and it might be the core target gene. Other top 5 genes (TP53, MAPK1, CDKN1A, MYC, and DDX5) were selected as the key target gens. MDM2 can negatively regulate p53 which is a central cell cycle regulator and has a negatively regulatory effect on autoimmunity ([@B30]). MDM2 can block the transactivation domain of p53 and affects gene transcription by inhibiting the ability and then block the progression of cell cycle and promote apoptosis ([@B46]). MDM2 can regulate a functional autologous immune response; therefore, it is linked to the development of autoimmunity ([@B35]). Studies on the role of MDM2 in immune regulation illustrated that inhibition of MDM2 promoted T cell proliferation induced by dendritic cells ([@B8]). It is well-known that MAPKs are an essential regulator of immune responses. The TP53 gene provides instructions to make the p53 protein ([@B45]). The expression and stability of p53 can be promoted by inhibiting PKA and p53 phosphorylation inactivates BCL-XL, leading to platelet apoptosis ([@B57]). Research found that CDKN1A has a potential pro-apoptotic effect by reason of arresting cells at G1 or G2/M phases ([@B16]). CDKN1A protein is also a p53 transcriptional target and can activate cell cycle checkpoints, promote DNA repair, downregulate apoptosis, and trigger a senescence-like growth arrested response, all of which play an important role in the network of DNA damage surveillance ([@B36]). MYC has been suggested to directly coordinate the immune response through regulating the immune checkpoints expression ([@B3]). It has been widely accepted that the role of Th17 cells in ITP is a possible pathogenic factor and a potential therapeutic target of ITP ([@B51]). DDX5 was found to control the differentiation of Th17 cells at steady state and autoimmunity ([@B15]).

The mechanisms of action and molecular targets of YQSX for ITP were explored using a network pharmacology approach in this study. Kaempferol, glycine, and stigmasterol regulated the most targets associated with ITP. YQSX may regulate immunological function through the specific biological processes including gene silencing, gene expression, apoptotic process, and signal transduction by p53 class mediator and the related pathways including MAPK signaling pathway and PI3K-AKT signaling pathway. In addition, YQSX may exert its regulatory function in the pathogenesis of ITP and the regulation of pathways including proteoglycans in cancer, prostate cancer, glioma, and thyroid hormone and estrogen signaling pathways which are associated with the occurrence of ITP. MDM2, TP53, MAPK1, CDKN1A, MYC, and DDX5 were the key target gens in the gene network of YQSX for treatment of ITP. The network pharmacology appears to be a suitable approach for the study of complex TCM formulations.
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